


## CLAIMS

We claim:

1. A compound of Formula (I):



5

or a pharmaceutically acceptable salt, hydrate or solvate thereof,

wherein:

R<sub>1</sub> is H or C<sub>1-6</sub> alkyl;

R<sub>2</sub> is H, halogen, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> haloalkyl; and

10 A) R<sub>3</sub> is aryl, C<sub>3-7</sub> cycloalkyl, C<sub>3-7</sub> cycloalkenyl, heteroaryl, C<sub>3-7</sub> heterocycloalkyl or C<sub>3-7</sub> heterocycloalkenyl wherein each are optionally substituted with 1 to 5 substituents selected from the group consisting of C<sub>1-6</sub> acyloxy, C<sub>2-6</sub> alkenyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylcarboxamide, C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> alkylsulfonamide, C<sub>1-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkylsulfonyl, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> alkylureyl, C<sub>1-6</sub> alkylamino, amino, aryl, substituted aryl, carbo-C<sub>1-6</sub>-alkoxy, carboxamide, cyano, C<sub>3-7</sub> cycloalkyl, C<sub>2-6</sub> dialkylamino, C<sub>2-6</sub> dialkylcarboxamide, C<sub>2-6</sub> dialkylsulfonamide, halogen, C<sub>1-6</sub> haloalkoxy, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> haloalkylsulfinyl, C<sub>1-6</sub> haloalkylsulfonyl, C<sub>1-6</sub> haloalkylthio, heteroaryl, substituted heteroaryl, hydroxyl, nitro and thiol; and

15

15

20

R<sub>4</sub> is selected from the group consisting of H, ethyl, n-propyl, C<sub>4-6</sub> alkyl and C<sub>1-6</sub> haloalkyl wherein each are optionally substituted with 1 to 5 substituents selected from the group consisting of C<sub>1-6</sub> acyloxy, C<sub>2-6</sub> alkenyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylcarboxamide, C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> alkylsulfonamide, C<sub>1-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkylsulfonyl, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> alkylureyl, C<sub>1-6</sub> alkylamino, amino, carbo-C<sub>1-6</sub>-alkoxy, carboxamide, cyano, C<sub>3-7</sub> cycloalkyl, C<sub>2-6</sub> dialkylamino, C<sub>2-6</sub> dialkylcarboxamide, C<sub>2-6</sub> dialkylsulfonamide, halogen, C<sub>1-6</sub> haloalkoxy, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> haloalkylsulfinyl, C<sub>1-6</sub> haloalkylsulfonyl, C<sub>1-6</sub> haloalkylthio, hydroxyl, nitro and thiol; or

25

30

R<sub>4</sub> is C<sub>3-6</sub>-cycloalkyl optionally substituted with 1 to 5 substituents selected from the group consisting of C<sub>1-6</sub> acyloxy, C<sub>2-6</sub> alkenyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylcarboxamide, C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> alkylsulfonamide, C<sub>1-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkylsulfonyl, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> alkylureyl, C<sub>1-6</sub> alkylamino, amino, carbo-C<sub>1-6</sub>-alkoxy, carboxamide, cyano, C<sub>3-7</sub> cycloalkyl, C<sub>2-6</sub> dialkylamino, C<sub>2-6</sub> dialkylcarboxamide, C<sub>2-6</sub> dialkylsulfonamide, halogen, C<sub>1-6</sub> haloalkoxy, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> haloalkylsulfinyl, C<sub>1-6</sub> haloalkylsulfonyl, C<sub>1-6</sub> haloalkylthio, hydroxyl, nitro and thiol;

or

B) R<sub>3</sub> is a substituted phenyl, 2-chlorophenyl, 3-chlorophenyl, naphthyl, C<sub>3-7</sub> cycloalkyl, C<sub>3-7</sub> cycloalkenyl, heteroaryl, C<sub>3-7</sub> heterocycloalkyl or C<sub>3-7</sub> heterocycloalkenyl wherein

said 2-chlorophenyl, 3-chlorophenyl, naphthyl, C<sub>3-7</sub> cycloalkyl, C<sub>3-7</sub> cycloalkenyl, heteroaryl, C<sub>3-7</sub> heterocycloalkyl and C<sub>3-7</sub> heterocycloalkenyl are optionally substituted with 1 to 5 substituents selected from the group consisting of C<sub>1-6</sub> acyloxy, C<sub>2-6</sub> alkenyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylcarboxamide, C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> alkylsulfonamide, C<sub>1-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkylsulfonyl, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> alkylureyl, C<sub>1-6</sub> alkylamino, amino, aryl, substituted aryl, carbo-C<sub>1-6</sub>-alkoxy, carboxamide, cyano, C<sub>3-7</sub> cycloalkyl, C<sub>2-6</sub> dialkylamino, C<sub>2-6</sub> dialkylcarboxamide, C<sub>2-6</sub> dialkylsulfonamide, halogen, C<sub>1-6</sub> haloalkoxy, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> haloalkylsulfinyl, C<sub>1-6</sub> haloalkylsulfonyl, C<sub>1-6</sub> haloalkylthio, heteroaryl, substituted heteroaryl, hydroxyl, nitro and thiol; and

R<sub>4</sub> is selected from the group consisting of H, C<sub>1-6</sub> alkyl, C<sub>3-6</sub>-cycloalkyl and C<sub>1-6</sub> haloalkyl wherein each are optionally substituted with 1 to 5 substituents selected from the group consisting of C<sub>1-6</sub> acyloxy, C<sub>2-6</sub> alkenyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylcarboxamide, C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> alkylsulfonamide, C<sub>1-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkylsulfonyl, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> alkylureyl, C<sub>1-6</sub> alkylamino, amino, carbo-C<sub>1-6</sub>-alkoxy, carboxamide, cyano, C<sub>3-7</sub> cycloalkyl, C<sub>2-6</sub> dialkylamino, C<sub>2-6</sub> dialkylcarboxamide, C<sub>2-6</sub> dialkylsulfonamide, halogen, C<sub>1-6</sub> haloalkoxy, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> haloalkylsulfinyl, C<sub>1-6</sub> haloalkylsulfonyl, C<sub>1-6</sub> haloalkylthio, hydroxyl, nitro and thiol.

2. The compound according to claim 1 wherein R<sub>1</sub> is C<sub>1-6</sub> alkyl.
- 20 3. The compound according to claim 1 wherein R<sub>1</sub> is methyl or ethyl.
4. The compound according to claim 1 wherein R<sub>1</sub> is H.
5. The compound according to any one of claims 1 to 4 wherein R<sub>2</sub> is H.
- 25 6. The compound according to any one of claims 1 to 5 wherein R<sub>4</sub> is C<sub>1-6</sub> alkyl.
7. The compound according to any one of claims 1 to 5 wherein R<sub>4</sub> is methyl.
- 30 8. The compound according to any one of claims 1 to 5 wherein R<sub>4</sub> is ethyl.
9. The compound according to any one of claims 1 to 5 wherein R<sub>4</sub> is C<sub>1-6</sub> haloalkyl.
10. The compound according to any one of claims 1 to 5 wherein R<sub>4</sub> is trifluoromethyl.
- 35 11. The compound according to any one of claims 1 to 10 wherein R<sub>3</sub> is substituted phenyl, 3-chlorophenyl, C<sub>3-7</sub> cycloalkyl, C<sub>3-7</sub> cycloalkenyl or heteroaryl, wherein said 3-chlorophenyl, C<sub>3-7</sub> cycloalkyl, C<sub>3-7</sub> cycloalkenyl and heteroaryl are optionally substituted with 1 to 5 substituents

selected from the group consisting of C<sub>2-6</sub> alkenyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkyl, aryl, cyano, halogen, C<sub>1-6</sub> haloalkyl and heteroaryl.

12. The compound according to any one of claims 1 to 10 wherein R<sub>3</sub> is thienyl optionally substituted with C<sub>1-6</sub> alkyl, halogen or C<sub>1-6</sub> haloalkyl.
- 5 13. The compound according to any one of claims 1 to 10 wherein R<sub>3</sub> is thienyl optionally substituted with methyl, ethyl, F, Cl, Br, I or trifluoromethyl.
- 10 14. The compound according to any one of claims 1 to 10 wherein R<sub>3</sub> is selected from the group consisting of biphenyl-3-yl, 3-thiophen-2-yl-phenyl, 3-bromo-phenyl, 3-iodo-phenyl, 3-chloro-phenyl, 3-fluoro-phenyl, 3,5-difluoro-phenyl, m-tolyl, 3-ethyl-phenyl, 3-trifluoromethyl-phenyl, 4-fluoro-phenyl, 2-fluoro-phenyl, 3,4-difluoro-phenyl, 2,4-difluoro-phenyl, 2,6-difluoro-phenyl, 2,5-dichloro-phenyl, 3-methoxy-phenyl, 3,5-dichloro-phenyl, 3-cyano-phenyl, 3-propenyl-phenyl, 3-hex-1-enyl-phenyl and 3-vinyl-phenyl.
- 15 15. The compound according to any one of claims 1 to 10 wherein R<sub>3</sub> is selected from the group consisting of thiophen-3-yl, thiophen-2-yl, 4-bromo-thiophen-2-yl, 5-methyl-thiophen-2-yl, 5-chloro-thiophen-2-yl, 5-bromo-thiophen-3-yl, 5-chloro-thiophen-3-yl, 4-bromo-5-methyl-thiophen-2-yl, pyridin-3-yl, furan-2-yl, 4-methyl-thiophen-2-yl and 5-methyl-thiophen-3-yl.
- 20 16. The compound according to any one of claims 1 to 10 wherein R<sub>3</sub> is selected from the group consisting of cyclohex-1-enyl, cyclopent-1-enyl and cyclopentyl.
- 25 17. The compound according to claim 1 wherein:
  - R<sub>1</sub> is H;
  - R<sub>2</sub> is H;
  - R<sub>4</sub> is C<sub>1-6</sub> alkyl or C<sub>1-6</sub> haloalkyl; and
  - R<sub>3</sub> is substituted phenyl, 3-chlorophenyl, C<sub>3-7</sub> cycloalkyl, C<sub>3-7</sub> cycloalkenyl or heteroaryl, wherein said 3-chlorophenyl, C<sub>3-7</sub> cycloalkyl, C<sub>3-7</sub> cycloalkenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of C<sub>2-6</sub> alkenyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkyl, aryl, cyano, halogen, C<sub>1-6</sub> haloalkyl and heteroaryl.
- 30 18. The compound according to claim 1 wherein:
  - R<sub>1</sub> is H;
  - R<sub>2</sub> is H;
  - R<sub>4</sub> is methyl, ethyl or trifluoromethyl; and
- 35

5                   R<sub>3</sub> is selected from the group consisting of biphenyl-3-yl, 3-thiophen-2-yl-phenyl, 3-bromo-phenyl, 3-iodo-phenyl, 3-chloro-phenyl, 3-fluoro-phenyl, 3,5-difluoro-phenyl, m-tolyl, 3-ethyl-phenyl, 3-trifluoromethyl-phenyl, 3,4-difluoro-phenyl, 2,4-difluoro-phenyl, 2,6-difluoro-phenyl, 2,5-dichloro-phenyl, 3-methoxy-phenyl, 3,5-dichloro-phenyl, 3-cyano-phenyl, 3-propenyl-phenyl, 3-hex-1-enyl-phenyl and 3-vinyl-phenyl.

19. The compound according to claim 1 wherein:

R<sub>1</sub> is H;

R<sub>2</sub> is H;

10                   R<sub>4</sub> is methyl, ethyl or trifluoromethyl; and

R<sub>3</sub> is thienyl optionally substituted with C<sub>1-6</sub> alkyl or halogen.

20. The compound according to claim 1 wherein:

R<sub>1</sub> is H;

15                   R<sub>2</sub> is H;

R<sub>4</sub> is methyl, ethyl or trifluoromethyl; and

20                   R<sub>3</sub> is selected from the group consisting of thiophen-3-yl, thiophen-2-yl, 4-bromo-thiophen-2-yl, 5-methyl-thiophen-2-yl, 5-chloro-thiophen-2-yl, 5-bromo-thiophen-3-yl, 5-chloro-thiophen-3-yl, 4-bromo-5-methyl-thiophen-2-yl, pyridin-3-yl, furan-2-yl, 4-methyl-thiophen-2-yl and 5-methyl-thiophen-3-yl.

21. The compound according to claim 1 selected from the group consisting of:

25                   5-Cyclohex-1-enyl-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;

5-Methyl-4-oxo-5-thiophen-3-yl-4,5-dihydro-furan-2-carboxylic acid methyl ester;

5-Methyl-4-oxo-5-thiophen-2-yl-4,5-dihydro-furan-2-carboxylic acid methyl ester;

30                   5-(4-Bromo-thiophen-2-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid methyl ester;

5-(4-Bromo-thiophen-2-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;

35                   5-Methyl-5-(5-methyl-thiophen-2-yl)-4-oxo-4,5-dihydro-furan-2-carboxylic acid methyl ester;

5-Methyl-5-(5-methyl-thiophen-2-yl)-4-oxo-4,5-dihydro-furan-2-carboxylic acid;

5-(5-Chloro-thiophen-2-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid methyl;

40                   5-Cyclopent-1-enyl-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;

5-Biphenyl-3-yl-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid methyl ester;

45                   5-Methyl-4-oxo-5-(3-thiophen-2-yl-phenyl)-4,5-dihydro-furan-2-carboxylic acid methyl ester;

5-(3-Bromo-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid methyl ester;

5-(3-Bromo-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
5-(3-Iodo-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
5-(3-Chloro-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
5-(3-Fluoro-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
5-(3,5-Difluoro-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
5-Methyl-4-oxo-5-m-tolyl-4,5-dihydro-furan-2-carboxylic acid;  
5-(3-Ethyl-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
5-Methyl-4-oxo-5-(3-trifluoromethyl-phenyl)-4,5-dihydro-furan-2-carboxylic acid;  
5-(5-Chloro-thiophen-2-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid; and  
10 5-Methyl-4-oxo-5-thiophen-2-yl-4,5-dihydro-furan-2-carboxylic acid; or  
a pharmaceutically acceptable salt, hydrate or solvate thereof.

22. The compound according to claim 1 selected from the group consisting of:

15 5-(5-Bromo-thiophen-3-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid methyl ester;  
5-(5-Bromo-thiophen-3-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
5-(5-Chloro-thiophen-3-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid methyl ester;  
20 5-(5-Chloro-thiophen-3-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
5-(4-Bromo-5-methyl-thiophen-2-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
5-Methyl-4-oxo-5-thiophen-3-yl-4,5-dihydro-furan-2-carboxylic acid;  
25 5-(4-Fluoro-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
5-Methyl-4-oxo-5-pyridin-3-yl-4,5-dihydro-furan-2-carboxylic acid;  
5-Ethyl-4-oxo-5-phenyl-4,5-dihydro-furan-2-carboxylic acid;  
5-(2-Fluoro-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
2-Methyl-3-oxo-2,3-dihydro-[2,2']bifuranyl-5-carboxylic acid;  
30 5-(3,4-Difluoro-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
5-(2,4-Difluoro-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
5-(2,6-Difluoro-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
5-(2,5-Dichloro-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
35 5-(3-Methoxy-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
5-Methyl-4-oxo-5-m-tolyl-4,5-dihydro-furan-2-carboxylic acid methyl ester;  
5-(3-Ethyl-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid methyl ester;  
5-Cyclohex-1-enyl-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid methyl ester;  
5-(3,5-Dichloro-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid methyl ester;  
5-(3,5-Dichloro-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;

5-(3-Iodo-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid methyl ester;  
5-Cyclopentyl-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid methyl ester;  
5-Cyclopentyl-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
5-(3-Cyano-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid methyl ester;  
5-(3-Cyano-phenyl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
5-Methyl-4-oxo-5-[3-propenyl]-phenyl]-4,5-dihydro-furan-2-carboxylic acid;  
5-(4-Bromo-5-methyl-thiophen-2-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid  
methyl ester;  
5-Biphenyl-3-yl-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
5-[3-Hex-1-enyl]-phenyl]-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
5-Methyl-5-(4-methyl-thiophen-2-yl)-4-oxo-4,5-dihydro-furan-2-carboxylic acid methyl  
ester;  
5-Methyl-4-oxo-5-(3-vinyl-phenyl)-4,5-dihydro-furan-2-carboxylic acid;  
5-Methyl-5-(4-methyl-thiophen-2-yl)-4-oxo-4,5-dihydro-furan-2-carboxylic acid;  
5-Methyl-5-(5-methyl-thiophen-3-yl)-4-oxo-4,5-dihydro-furan-2-carboxylic acid; and  
4-Oxo-5-phenyl-5-trifluoromethyl-4,5-dihydro-furan-2-carboxylic acid; or  
a pharmaceutically acceptable salt, hydrate or solvate thereof.

23. The compound according to any one of claims 1 to 22 wherein said compound is essentially the R  
20 enantiomer.

24. The compound according to any one of claims 1 to 22 wherein said compound is essentially the S  
enantiomer.

25. A pharmaceutical composition comprising a compound according to any one of claims 1 to 24 in  
20 combination with a pharmaceutically acceptable carrier.

26. A pharmaceutical composition according to claim 25 further comprising an agent selected from the  
30 group consisting of  $\alpha$ -glucosidase inhibitor, aldose reductase inhibitor, biguanide, HMG-CoA  
reductase inhibitor, squalene synthesis inhibitor, fibrate, LDL catabolism enhancer, angiotensin  
converting enzyme inhibitor, insulin secretion enhancer and thiazolidinedione.

27. A method of treatment of a metabolic-related disorder comprising administering to an individual  
35 in need of such treatment a therapeutically-effective amount of a compound according to any  
one of claims 1 to 24 or a pharmaceutical composition of claim 25 or 26.

28. The method according to claim 27 wherein said metabolic-related disorder is selected from the  
group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, obesity,

impaired glucose tolerance, atheromatous disease, hypertension, stroke, Syndrome X, heart disease and type 2 diabetes.

29. The method according to claim 27 wherein said metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.
- 5 30. The method according to claim 27 wherein said metabolic-related disorder is atherosclerosis.
- 10 31. A method of modulating a RUP25 receptor comprising contacting said receptor with a compound according to any one of claims 1 to 24 or a pharmaceutical composition of claim 25 or 26.
- 15 32. A method of modulating a RUP25 receptor for the treatment of a metabolic-related disorder in an individual in need of such modulation comprising contacting said receptor with a therapeutically-effective amount of a compound according to any one of claims 1 to 24 or a pharmaceutical composition of claim 25 or 26.
33. The method according to claim 31 or 32 wherein said compound is an agonist.
- 20 34. The method according to claim 33 wherein said agonist is a partial agonist.
35. A method of raising HDL in an individual comprising administering to said individual a therapeutically-effective amount of a compound according to any one of claims 1 to 24 or a pharmaceutical composition of claim 25 or 26.
- 25 36. The method according to any one of claims 27 to 35 wherein said individual is a mammal.
37. The method according to claim 36 wherein said mammal is a human.
- 30 38. A compound according to any one of claims 1 to 24 for use in a method of treatment of the human or animal body by therapy.
39. A compound according to any one of claims 1 to 24 for use in a method of treatment of a metabolic-related disorder of the human or animal body by therapy.
- 35 40. A compound according to any one of claims 1 to 24 for use in a method of treatment of a metabolic-related disorder of the human or animal body by therapy wherein said metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart

disease, insulin resistance, obesity, impaired glucose tolerance, atheromatous disease, hypertension, stroke, Syndrome X, heart disease and type 2 diabetes.

41. A compound according to any one of claims 1 to 24 for use in a method of treatment of a metabolic-related disorder of the human or animal body by therapy wherein said metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.
42. A compound according to any one of claims 1 to 24 for use in a method of treatment of atherosclerosis of the human or animal body by therapy.
43. A compound according to any one of claims 1 to 24 for use in a method of raising HDL of the human or animal body by therapy.
44. Use of a compound according to any one of claims 1 to 24 for the manufacture of a medicament for use in the treatment of a metabolic-related disorder.
45. Use of a compound according to any one of claims 1 to 24 for the manufacture of a medicament for use in the treatment of a metabolic-related disorder selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, obesity, impaired glucose tolerance, atheromatous disease, hypertension, stroke, Syndrome X, heart disease and type 2 diabetes.
46. Use of a compound according to any one of claims 1 to 24 for the manufacture of a medicament for use in the treatment of atherosclerosis.
47. Use of a compound according to any one of claims 1 to 24 for the manufacture of a medicament for use in raising HDL in an individual.
48. A method of producing a pharmaceutical composition comprising admixing a compound according to any one of claims 1 to 24 and a pharmaceutically acceptable carrier.